Cross-institution positioning
May 6, 2026Accumulation leaning. 1 accumulating across 1 comparable institution.
Source: Schedule 13 researchFoghorn Therapeutics Inc.
Latest stored close $2.00 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Accumulation leaning. 1 accumulating across 1 comparable institution.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/52 non-amendment material events in the last 90 days; Latest classified evidence: Exit or disposal activities. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +112.7% YoY; Net income +59.9% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 20% through its reported 52-week range; -17.4% over one year.
Source: Stored historical price seriesFiled May 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Lynch Thomas J. Jr. | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | Duty Stuart | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | Biller Scott | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | Gallagher Neil | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | Mendelsohn Michael | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | SMITH IAN F | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | GILL SIMBA | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | PARSHALL B LYNNE | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Jun 24, 2026 | Cole Douglas G. | AGrant, award, or other acquisition · derivative | Stock Options (Right to buy) | 28.0K | $4.08 | Direct | Jun 25, 2026 |
| Apr 10, 2026 | GOTTSCHALK ADRIAN | GGift | Common Stock | 59.2K | $0.00 | Indirect | Apr 13, 2026 |
| Apr 10, 2026 | GOTTSCHALK ADRIAN | GGift | Common Stock | 59.2K | $0.00 | Indirect | Apr 13, 2026 |
| Apr 9, 2026 | GOTTSCHALK ADRIAN | GGift | Common Stock | 47.5K | $0.00 | Indirect | Apr 13, 2026 |
| Apr 9, 2026 | GOTTSCHALK ADRIAN | GGift | Common Stock | 47.5K | $0.00 | Indirect | Apr 13, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Oct 1, 2026 | 8-K | 2.05, 7.01, 9.01 | Exit or disposal activities; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 6, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jun 24, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| May 7, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Apr 21, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Mar 26, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Mar 11, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Feb 23, 2026 | 8-K | 5.02, 8.01, 9.01 | Director or executive change; Other event; Financial statements / exhibits | — | Filing |
| Jan 12, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jan 12, 2026 | 8-K | 2.02, 7.01, 8.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Dec 4, 2025 | 8-K | 5.02 | Director or executive change | — | Filing |
| Nov 7, 2025 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $16.1M | +112.7% |
| Ended Mar 31, 2026 | $3.3M | -45.1% |
| Ended Sep 30, 2025 | $8.2M | +4.4% |
| Ended Jun 30, 2025 | $7.6M | +9.7% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $30.9M | +36.8% |
| Ended Dec 31, 2024 | $22.6M | -33.8% |
| Ended Dec 31, 2023 | $34.2M | +77.6% |
| Ended Dec 31, 2022 | $19.2M | +1,357.8% |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Mar 31, 2026 observed May 6, 2026 filed · 36d Schedule 13G amendment | Reported accumulation | 6.8M +1.1M | 12.00% +1.80 pts | $4.78 | $4.68 | $2.00 |
| Fidelity / FMR CIK0000315066 | Dec 31, 2024 observed Feb 12, 2025 filed · 43d Schedule 13G amendment | Reported reduction | 5.7M -613.5K | 10.20% -1.19 pts | $4.72 | $5.52 | $2.00 |
| Fidelity / FMR CIK0000315066 | Jun 10, 2024 observed Jun 10, 2024 filed · 0d Schedule 13G amendment | Reported accumulation | 6.3M +3.5M | 11.39% +4.74 pts | $5.82 | $5.82 | $2.00 |
Compare FHTX with other securities showing similar institutional activity or recent accumulation across several tracked institutions.